Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: KTTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pasithea Therapeutics Corp. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and warrants. The company’s 8-K reports cover executive appointments, Regulation FD communications, shareholder voting matters, equity incentive plan approvals, Nasdaq continued-listing compliance and other material events.
Pasithea’s registration statements describe securities offerings, capital structure, emerging growth company status and risk disclosures related to biotechnology research and development. Its filings also identify the company’s Delaware incorporation, Miami Beach executive office, common stock under KTTA and warrants under KTTAW.
Pasithea Therapeutics Corp. reported progress in its Phase 1/1b study of PAS-004 in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas. The company has activated two clinical trial sites in South Korea, Asan Medical Centre and Severance Hospital Yonsei University Health System, which are now recruiting, and the first South Korean patient has been dosed.
Globally, the NF1 trial has moved from Cohort 1, a 4mg tablet dose, to enrolling patients in Cohort 2 at an 8mg tablet dose after an external Safety Review Committee recommended proceeding without modification. Initial interim clinical data from the first two cohorts are expected in the first quarter of 2026, which will begin to show how PAS-004 is performing on safety, tolerability, pharmacokinetics and pharmacodynamics in this NF1 population.